Skip to main content
. 2015 Jul 14;6(29):27440–27460. doi: 10.18632/oncotarget.4578

Figure 6. Antitumor activity of galeterone and VNPT55 in a CWR22Rv1 xenograft.

Figure 6

Figure 6

A. Representative tumors from the 2 groups. Effect of gal and VNPT55 was evaluated in castrated CWR22Rv1 xenograft-bearing mice. Mice (n = 5) were administered with gal (0.15 mmol/kg/twice daily) and VNPT55 (0.15 mmol/kg/twice daily), by intraperitoneal injection, 5 days per week for 34 days. Tumors were measured twice a week. B. Mean body weights of mice were weighed once a week for the duration of the study. C. Hematoxylin and eosin staining of normal organs, formalin fixed and paraffin embedded tissues to show in vivo and off-target toxicity or not of compounds. D. Representative images of full length AR, AR-3 and PCNA immunostaining in vehicle and treated groups. E. ImageJ was used to quantify Immunohistochemical staining in D. E. ImageJ was used to quantify Immunohistochemical staining in D. F. Xenograft tumor tissues were harvested and analyzed by western blotting. Effects on fAR, AR-V7, cyclin D1, Bcl2 and Bax were analyzed in both galeterone and VNPT55 groups compared to controls. G. Densitometry analysis of protein expression from western blot analysis was plotted to quantify the effects seen in vivo.